Soluciones API

El negocio API del Dr. Reddy suministra API asequibles y de alta calidad a los principales fabricantes de formulaciones genéricas y es el socio API preferido por las compañías farmacéuticas en más de 100 países.

I+D

Dr. Reddy’s suministra API genéricas a más de 80 países, destacándose en I+D en moléculas de nicho y terapias clave, con capacidades desde el laboratorio hasta la producción en API contenidas/no contenidas y procesos químicos avanzados.

Libro Blanco

Dr. Reddy's ofrece documentos técnicos esclarecedores que comparten su experiencia sobre API, formulaciones, tendencias regulatorias e innovaciones de la industria, ayudando a los socios farmacéuticos globales a adquirir conocimientos, resolver desafíos e

CPHI China 2026

Visit us to learn how Dr. Reddy’s can be your strategic partner across markets.

Meet us at Booth No. E1H28

16-18 June 2026
New International Expo Center, Shanghai, China

Phone

Our Team at CPHI China 2026

Deepak Sapra

CEO, Pharmaceutical Services and Active Ingredients

Nirav Shah

Vice President, and Head, API - North Asia

Tammy Tang

Director Sales And Marketing

Kundan Reddy

Director - Sales And Marketing

Jayce Yang

Associate Director, Sales & Marketing

About Dr.Reddy's API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy’s API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

250+ APIs
8 Manufacturing sites
2000+ drug master files across global markets.
Over 325 ANDAs
Filed 1100+ patents filed globally
Experience with complex APIs and formulations supporting early market entries
Preferred pharma API supplier for pharma companies in more than 80 countries

Sustainability is deeply embedded in our purpose and forms the core of our organization.

Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability. By the end of FY2025, we had served over 756 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.

Our ESG (Environment, Social & Governance) Goal:

Building the future responsibly

Our ESG goals are deeply embedded in our business strategy, guiding our efforts to create a significant and lasting positive impact on the planet and its people. We have made fair progress across several of these goals, even as a few continue to present challenges. We are committed to advancing our ESG journey, ensuring that as we prosper, we do so responsibly and with resilience.

What we achieved in the past year:

3.8

Bn total revenue (17% growth)

165

New products launched

111

DMFs filed, (1,630+ Cumulative DMFs)

249

Dossiers, including 10 ANDAs filed

76

Filings in the US pending for approval

20.4%

Women in leadership

96%

Employees trained for skill upgradation

0.14 to 0.07

*LTIFR reduced from

126

Differently abled employees

700,000+

Lives impacted through CSR

783

Million KL of water saved through agri-water saving techniques

66,723

MTCO2e of direct emissions reduction

11%

Reduction in water intensity per rupee of turnover with respect to FY2024

60%

Carbon neutrality achieved

75,761

KL of harvested rainwater used

54%

Water reused/recycled

Our Plants

What We Present at CPHI China 2026

APIs for Global Markets, Including China

A strong and diversified API portfolio across major therapeutic areas:
Cardiovascular, CNS, Gastro‑Intestinal, Anti‑infectives, Oncology, Dermatology, and Metabolic disorders
APIs with China DMF, USDMF, and EU DMF coverage
Complex APIs and value‑added technologies
Pipeline APIs aligned with future market and regulatory needs
Support for both commercial supply and development programs

Finished Dosage Forms (FDFs)

We showcase our formulation and manufacturing capabilities across:
Oral solid dosage forms, injectables, and complex generics
R&D‑driven formulation expertise
Supply partnerships, in‑licensing, and out‑licensing opportunities
End‑to‑end support from development to commercialization

Peptides Capabilities:

cGMP manufacturing supported by robust quality systems
Flexible and scalable production, from grams to multi‑kg
A strong global regulatory track record
Collaboration opportunities for peptide development through Aurigene and Dr. Reddy’s
Support for clinical, development, and commercial supply

CDMO & Custom Services

Comprehensive, end‑to‑end development and manufacturing services
API development and scale‑up
Peptide synthesis and manufacturing
Small‑molecule CDMO services
Custom synthesis and process optimization
Seamless clinical‑to‑commercial supply

Biosimilars

We present our global biosimilar portfolio with partnership opportunities for China and international markets:
Commercial and late‑stage biosimilars
Flexible licensing and partnership models
High‑quality, affordable biologics supported by strong clinical data

B2B Collaborations